Janssen Ending Mosaico HIV Vaccine Trial
Janssen and its global partners say they are ending the Phase 3 Mosaico HIV vaccine trial following an independent, scheduled data review that found the regimen was not effective in preventing HIV infection compared to a placebo among study participants. A Janssen statement says no safety issues with the vaccine regimen were identified.